Considerations for expanding international reference pricing beyond Medicare Part B

Last fall, the Trump¬†administration¬†announced that it was exploring an international reference pricing model for drugs covered under Part B of Medicare (which are generally drugs administered by a physician, such as many chemotherapy drugs). Under this model, the amount Medicare would pay for these drugs would be set based on the average price paid in … Continue reading Considerations for expanding international reference pricing beyond Medicare Part B